Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 3,058 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Colon Clear all

Conditions: Colorectal Surgery, Colorectal Neoplasms, Colitis, Ulcerative, Diverticulitis, Colonic Polyps
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colorectal Cancer
Interventions: celecoxib, fluorouracil, conventional surgery, radiation therapy, tumor biopsy, laboratory biomarker analysis; Drug · Procedure · Radiation + 1 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: CRC (Colorectal Cancer)
Interventions: INCA33890, Placebo, Bevacizumab, FOLFOX; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 78
States / cities: Mobile, Alabama • Tucson, Arizona • Fountain Valley, California + 65 more

Conditions: Colon Cancer, Pancreas Cancer, Digestive Cancer
Interventions: CEND-1, Panitumumab, Folfirinox; Drug
Lead sponsor: Anup Kasi; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri

Conditions: Neoplasm Metastases, Melanoma, Colorectal Neoplasms
Interventions: Irinotecan, Chemoembolization, Drug-Eluting Beads, Biopsy; Drug · Procedure · Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 84 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colo-rectal Cancer
Interventions: Decision Counseling Session; Behavioral
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Lung Cancer, Colorectal Cancer
Interventions: Focus groups; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Colon Cancer, Metastatic Colon Cancer
Interventions: ST316, FOLFIRI regimen & bevacizumab, Fruquintinib, Lonsurf & bevacizumab; Drug
Lead sponsor: Sapience Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
Interventions: JAB-3068; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more

Conditions: Adenoma, Colorectal Cancer
Interventions: ENDOCUFF VISION® device, G-EYE® colonoscope; Device
Lead sponsor: Dr. Horst Schmidt Klinik GmbH; Industry
Eligibility: Not listed
Enrollment: 970 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Indianapolis, Indiana • New York, New York

Conditions: ColoRectal Cancer
Interventions: Screening patient navigation, Non-Navigated; Behavioral
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 50 Years to 85 Years
Enrollment: 415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Colon Cancer, Gastrointestinal Cancer
Interventions: PoZibio, Inert placebo; Dietary Supplement
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Interventions: BI 765049, ezabenlimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more

Conditions: Garden-fresh Produce and Exercise (GFPE)
Interventions: Garden-fresh produce and exercise; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions: RO7198457 intravenous (IV), Observational group (no intervention); Drug · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: embolization therapy; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Esophageal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Locally Advanced Urothelial Carcinoma, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Cutaneous Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration; Other · Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Colorectal Cancer
Interventions: Petosemtamab, Cetuximab, Bevacizumab, 5-FU, Leucovorin (Calcium Folinate), Oxaliplatin, Irinotecan; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 2 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: monoclonal antibody 11D10 anti-idiotype, monoclonal antibody 3H1 Alu Gel; Biological
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 75
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more

Conditions: Colorectal Cancer
Interventions: DNA stability analysis, gene rearrangement analysis; Genetic
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 11
States / cities: Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 8 more

Conditions: Breast Cancer, Colorectal Cancer, Covid19
Interventions: Informational videos and social media campaigns encouraging cancer screening.; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pawtucket, Rhode Island

Conditions: Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cancer of Colon, Cancer of Rectum
Interventions: Colorectal Health Research Champions; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 30 Years to 99 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Durvalumab, Radiation Therapy, Tremelimumab; Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 41
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more

Search by objective public record fields.

Follow-Up Phone Calls After Colorectal Surgery

Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads

Decision Counseling and Follow-up for Shield+ Patients

Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

Community Engaged Colon Cancer Screening Patient Navigator Program

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

Garden-fresh Produce and Exercise Reduce Colon Cancer Risk

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Genetic Study of Patients and Families With a History of Colorectal Cancer

Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island

Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder

Colorectal Health Research Champions

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer